個案總覽

The case describes Microsoft's first significant acquisition in Europe and its first in the telecom equipment (software) market. SendIt is a publicly listed Swedish start-up, which offers the only Windows based solutions to the IP-based mobile phone services market. The acquisition starts in high tone, loses momentum and is finally integrated with some degree of success.

This case tracks the evolution from October 2000 to July 2001 of public debate, regulatory decisions, and firm perspectives on the subject of consulting by accounting firms.

Supplements the (A) case.

Can you really change your behavior at work? What if you believe your approach has served you well in the past and helped you succeed to where you are today? This series of cases features Nicholas Gray, a Norfolk Southern Railroad (NS) executive and his experiences in implementing change from a middle manager position. The A case (UVA-OB-0773) begins with Gray identifying a change effort to build a better relationship with colleagues in other departments at NS. As the story unfolds, Gray's management style and some challenges he faces take shape. In the B case, Gray works through his action plan and the implementation of his change initiative. These cases provide an insight into the challenges of being a change agent at both personal and organizational levels.

Supplements the (A) case.

Supplements the (A) case.

Supplements Peter Isenberg at Jones Mendel (A).

Supplements the (A) case.

Supplements the (A) case.

Second in a three-part series that explores the multifaceted organizational and strategic choices that companies now face as a result of the global AIDS epidemic. Heineken is considering becoming one of the first companies to offer AIDS drugs (antiretroviral therapy) to employees and their families. Hans Wesseling, the corporate HR manager, and his colleagues in the medical department must consider the organizational, financial, and social impact of this decision and present a recommendation to the board. Shows how Heineken is responding to the epidemic and considering it as part of the company's corporate social responsibility.

Third in a three-part series that explores the multifaceted organizational and strategic choices that companies now face as a result of the global AIDS epidemic. Heineken is considering becoming one of the first companies to offer AIDS drugs (antiretroviral therapy) to employees and their families. Hans Wesseling, the corporate HR manager, and his colleagues in the medical department must consider the organizational, financial, and social impact of this decision and present a recommendation to the board. Shows how Heineken is responding to the epidemic and considering it as part of the company's corporate social responsibility.

Supplements the (A) case.

Supplements the (A) case.

Supplements the (A) case.

Supplements the (A) case.

The follow-on to the GSI A case presents the alternatives available to GSI in the summer of 1995. Former senior manager Gluntz has returned in February after a 10 year hiatus and created a plan to turnaround the company. By summer, it's obvious that the option of selling GSI to an appropriate acquirer must be evaluated, given the mounting pressure of financial investors. The case places the reader in Gluntz's shoes to determine whether to resuscitate the company from crisis or sell to one of three alternative buyers, one being ADP.

In July 1996, the French social security governmental agency (the CNAM) sent a letter to all doctors urging them to prescribe generic amoxicillin instead of Clamoxyl, SmithKline Beecham's (SB) blockbuster antibiotic. Pierre Chahwakilian, Marketing Director of SB in France must decide how to respond: (1) milk Clamoxyl and divert promotional investments towards Augmentin, a more specialized and still patent-protected antibiotic, (2) strengthen Clamoxyl's brand equity among doctors by increasing the effort of medical reps, by launching new forms, or with new advertising, (3) go against SB's corporate philosophy and reduce the price of Clamoxyl, or (4) change nothing and count on the resistance of French doctors towards generics. The B case (Augmentin in 2002) shows that GSK (the company formed by the merger of Glaxo Wellcome and SmithKline Beecham) now faces the same options for Augmentin, another blockbuster antibiotic. Should they use the strategy that was so successful for Clamoxyl or have the market conditions changed so much that a whole different approach should be followed?

This is a supplement to Julie Dempster (A), product 9B03C011. A newly hired vice-president of brand positioning must decide whether to renew her contract after experiencing cross-cultural and equality issues.

In this supplement to Westwood Securities (A), product 9B03C017, a junior broker has accepted a promotion to senior broker. Since the promotion, his sales have declined and he is wondering if made the right choice.

This supplement to Harrison-Lockington (A), product 9B03C019 follows the partner of a law firm and how he responds to crisis in the office - he has found out that an employee has been stealing from the firm.